português │español New York, 26 September 2024 – The Pan American Health Organization (PAHO) and the Global Antibiotic Research & Development Partnership (GARDP) have signed an agreement … PAHO and GARDP will collaborate to tackle antibiotic resistance in Latin America and the Caribbean
Announcements demonstrate momentum towards expanding access ahead of UN High-Level Meeting on AMR in New York New investments will ensure more people get access to … Funders invest an unprecedented EUR 60 million in innovative antibiotic R&D and access partnership
Geneva, 16 September 2024 – The UK Department of Health and Social Care has renewed its support to the Global Antibiotic Research & Development Partnership … UK Government commits new funding to accelerate antibiotic development and access for low- and middle-income countries
Geneva, 12 September 2024—The Government of Japan has granted additional funding to the Global Antibiotic Research & Development Partnership (GARDP) to support its vital work … Japan government’s new funding of GARDP signals continued commitment to tackling antibiotic resistance
Geneva and Bangalore, 11 June 2024 – The Global Antibiotic Research & Development Partnership (GARDP) and Bugworks Research Inc. (Bugworks) today announced a collaboration agreement to co-develop … Novel broad-spectrum antibiotic compound prioritized for development in fight against AMR
Geneva, 29 May 2024 – The Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership’s Global Drug Facility (GDF), hosted by UNOPS, … New partnership to improve access to new antibiotics in low- and middle-income countries to boost efforts to combat TB and AMR
Geneva, 21 May 2024 – The Global Antibiotic Research and Development Partnership (GARDP) is pleased to announce renewed funding from the South African Medical Research … The South African Medical Research Council renews funding for GARDP’s work in neonatal sepsis
Top-line study results represent a significant milestone in the development of a novel antibiotic against drug-resistant Neisseria gonorrhoea, a high priority pathogen. ESCMID Global 2024 … GARDP to present positive phase 3 trial results for zoliflodacin at ESCMID Global 2024
Geneva, 21 February 2024 – The Global Antibiotic Research & Development Partnership (GARDP) announced today an additional investment of £2.5 million from the UK Government. The … UK Government pledges £2.5 million towards new antibiotic treatments
Geneva, Switzerland, 20 November 2023 – In a boost to efforts to counter antibiotic resistance, the Research Investment for Global Health Technology (RIGHT) Foundation has … The RIGHT Foundation invests in new treatments for neonatal sepsis